| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Colonna, P Saleem, L Dondey-Nouvel, W Rei. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. International clinical psychopharmacology. vol 15. issue 1. 2000-09-25. PMID:10836281. |
in this long-term, open, randomised, multicentre trial, patients with chronic or subchronic schizophrenia received amisulpride (n =370) or haloperidol (n = 118) for 12 months. |
2000-09-25 |
2023-08-12 |
Not clear |
| H J Mölle. Amisulpride: a review of its efficacy in schizophrenia. Acta psychiatrica Scandinavica. Supplementum. vol 400. 2000-08-29. PMID:10823307. |
amisulpride: a review of its efficacy in schizophrenia. |
2000-08-29 |
2023-08-12 |
Not clear |
| J Peusken. Amisulpride: its role in the therapeutic management of the schizophrenia patient. Conclusions. Acta psychiatrica Scandinavica. Supplementum. vol 400. 2000-08-29. PMID:10823309. |
amisulpride: its role in the therapeutic management of the schizophrenia patient. |
2000-08-29 |
2023-08-12 |
Not clear |
| J Peuskens, P Bech, H J Möller, R Bale, O Fleurot, W Rei. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry research. vol 88. issue 2. 2000-02-08. PMID:10622347. |
amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. |
2000-02-08 |
2023-08-12 |
Not clear |
| J Peuskens, P Bech, H J Möller, R Bale, O Fleurot, W Rei. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry research. vol 88. issue 2. 2000-02-08. PMID:10622347. |
amisulpride, a substituted benzamide with high selectivity for dopamine d3 and d2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia. |
2000-02-08 |
2023-08-12 |
Not clear |
| A Patat, P Rosenzweig, N Miget, H Allain, J M Gando. Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects. Fundamental & clinical pharmacology. vol 13. issue 5. 1999-11-10. PMID:10520732. |
amisulpride is an active antipsychotic compound effective at low doses for negative symptoms and at high doses for positive symptoms of schizophrenia. |
1999-11-10 |
2023-08-12 |
human |
| C Coulouvrat, L Dondey-Nouve. Safety of amisulpride (Solian): a review of 11 clinical studies. International clinical psychopharmacology. vol 14. issue 4. 1999-10-14. PMID:10468313. |
we assessed the overall safety profile of amisulpride based on the results from 11 clinical studies performed in patients suffering from schizophrenia with predominance of positive or negative symptoms. |
1999-10-14 |
2023-08-12 |
Not clear |
| [Amisulpride--a neuroleptic agent for all phases of schizophrenia]. Der Nervenarzt. vol 70. issue 3 Suppl Amisulprid. 1999-05-03. PMID:10221135. |
[amisulpride--a neuroleptic agent for all phases of schizophrenia]. |
1999-05-03 |
2023-08-12 |
Not clear |
| H Wetzel, G Gründer, A Hillert, M Philipp, W F Gattaz, H Sauer, G Adler, J Schröder, W Rein, O Benker. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology. vol 137. issue 3. 1998-10-28. PMID:9682999. |
amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective d2-like antagonist to a mixed d1-/d2-like antagonist. |
1998-10-28 |
2023-08-12 |
Not clear |
| A Puech, O Fleurot, W Rei. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta psychiatrica Scandinavica. vol 98. issue 1. 1998-10-28. PMID:9696517. |
amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. |
1998-10-28 |
2023-08-12 |
Not clear |
| A Puech, O Fleurot, W Rei. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta psychiatrica Scandinavica. vol 98. issue 1. 1998-10-28. PMID:9696517. |
this 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia. |
1998-10-28 |
2023-08-12 |
Not clear |
| S Reid, J Turne. Amisulpride in schizophrenia. The British journal of psychiatry : the journal of mental science. vol 172. 1998-10-05. PMID:9747415. |
amisulpride in schizophrenia. |
1998-10-05 |
2023-08-12 |
Not clear |
| A Cudennec, D Fage, J Bénavidès, B Scatto. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat. Brain research. vol 768. issue 1-2. 1997-12-18. PMID:9369323. |
amisulpride, a benzamide derivative with an atypical neuroleptic profile relieves the negative symptoms of schizophrenia when administered at low doses (50-150 mg). |
1997-12-18 |
2023-08-12 |
rat |
| H J Möller, P Boyer, O Fleurot, W Rei. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology. vol 132. issue 4. 1997-10-31. PMID:9298518. |
improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. |
1997-10-31 |
2023-08-12 |
Not clear |
| H J Möller, P Boyer, O Fleurot, W Rei. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology. vol 132. issue 4. 1997-10-31. PMID:9298518. |
this study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia. |
1997-10-31 |
2023-08-12 |
Not clear |
| H L Freema. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. International clinical psychopharmacology. vol 12 Suppl 2. 1997-08-28. PMID:9218163. |
amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. |
1997-08-28 |
2023-08-12 |
human |
| W Rein, S Turjansk. Clinical update on amisulpride in deficit schizophrenia. International clinical psychopharmacology. vol 12 Suppl 2. 1997-08-28. PMID:9218164. |
clinical update on amisulpride in deficit schizophrenia. |
1997-08-28 |
2023-08-12 |
Not clear |
| W Rein, S Turjansk. Clinical update on amisulpride in deficit schizophrenia. International clinical psychopharmacology. vol 12 Suppl 2. 1997-08-28. PMID:9218164. |
in three double-blind studies, two short-term and one medium/long-term, comparing amisulpride with placebo, 272 patients with schizophrenia were carefully selected for a predominance of negative symptoms (low severity of positive symptoms, depression and extrapyramidal side effects). |
1997-08-28 |
2023-08-12 |
Not clear |
| B Scatton, Y Claustre, A Cudennec, A Oblin, G Perrault, D J Sanger, H Schoemake. Amisulpride: from animal pharmacology to therapeutic action. International clinical psychopharmacology. vol 12 Suppl 2. 1997-08-28. PMID:9218165. |
the atypical neurochemical and psychopharmacological profiles of amisulpride may explain its therapeutic efficacy on both positive and negative symptoms of schizophrenia. |
1997-08-28 |
2023-08-12 |
mouse |
| H Loo, M F Poirier-Littre, M Theron, W Rein, O Fleuro. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. The British journal of psychiatry : the journal of mental science. vol 170. 1997-04-04. PMID:9068769. |
amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. |
1997-04-04 |
2023-08-12 |
Not clear |